 |
|
Effect of Ritonavir on Saquinavir Metabolism
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The Consensus Statement on antiretroviral therapy in adults by Dr Carpenter and colleagues1 contains an inaccuracy regarding the effect of coadministration of ritonavir on the exposure of saquinavir in the soft-gelatin formulation (saquinavir SGF). Table 2 states that ritonavir coadministration results in an increase in saquinavir exposure (area under the plasma concentration curve [AUC]) of 121%. This estimate, however, is too low by greater than an order of magnitude.2
The increase of 121% results from a comparison of the 24-hour saquinavir exposures obtained with the combination of 400 mg of ritonavir twice daily plus 400 mg of saquinavir SGF twice daily against exposures obtained with saquinavir SGF, 1200 mg, administered 3 times daily (the licensed dosage).3-4 This comparison was previously presented because it was considered to be clinically meaningful in view of the wide use of the ritonavir, 400 mg, and saquinavir SGF, 400 mg, twice daily . . . [Full Text of this Article]
RELATED ARTICLE
Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel
Charles C. J. Carpenter, David A. Cooper, Margaret A. Fischl, Jose M. Gatell, Brian G. Gazzard, Scott M. Hammer, Martin S. Hirsch, Donna M. Jacobsen, David A. Katzenstein, Julio S. G. Montaner, Douglas D. Richman, Michael S. Saag, Mauro Schechter, Robert T. Schooley, Melanie A. Thompson, Stefano Vella, Patrick G. Yeni, and Paul A. Volberding
JAMA. 2000;283(3):381-390.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir, Nelfinavir, and Saquinavir after Simultaneous and Staggered Oral Administration
Lu et al.
Drug Metab. Dispos. 2002;30:1455-1461.
ABSTRACT
| FULL TEXT
|
